FDA Approves PhotoMedex Laser System for Dermatitis
RADNOR, Pa., Aug. 15 -- PhotoMedex Inc. has received US Food and Drug Administration (FDA) clearance to market the XTRAC laser system to treat atopic dermatitis. Atopic dermatitis, or eczema, is a chronic inflammation of the skin that can afflict persons of any age, but is considered to be the most common skin disease in children under the age of 11.
Jeff O'Donnell, President and CEO, commented, "We are very pleased to have received approval from the FDA so quickly. With 15 million Americans suffering from the disease, the ability to now treat eczema is another significant opportunity to expand the treatment platform for our XTRAC laser."
LATEST NEWS
- CLEO Heads to the East Coast
Apr 29, 2024
- Laser-Based Gas Analyzer Developed to Detect Air Pollution
Apr 29, 2024
- Qubits Could be Stored in Flash-Like Memory
Apr 29, 2024
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024